Assertio (ASRT) Exceeds Q3 Earnings and Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy ASRT?
Source: NASDAQ.COM
Earnings Performance: Assertio (ASRT) reported quarterly earnings of $0.11 per share, exceeding expectations of a loss of $0.08 per share, marking a significant earnings surprise of +237.50%.
Revenue Growth: The company generated revenues of $49.46 million for the quarter, surpassing the Zacks Consensus Estimate by 83.86% and showing a year-over-year increase from $29.2 million.
Stock Outlook: Assertio shares have declined by 12.7% year-to-date, underperforming the S&P 500, and currently hold a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Medical - Drugs industry, to which Assertio belongs, ranks in the top 37% of Zacks industries, suggesting that industry performance could significantly influence Assertio's stock movement in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.010
Low
35.00
Averages
40.00
High
45.00
Current: 18.010
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Whitestone REIT (NYSE: WSR) for its sale to Ares Management Corporation at $19.00 per share, potentially violating fiduciary duties to shareholders.
- Merger Implications: The merger between McCormick & Company (NYSE: MKC) and Unilever's Foods business will result in McCormick shareholders owning 35.0% of the combined entity, which may affect shareholder rights.
- Acquisition Scrutiny: Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) is under investigation regarding its merger with American Ocean Minerals Corporation, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations aimed at advocating for investors affected by securities fraud and corporate misconduct, highlighting its successful track record in recovering losses for defrauded investors.
See More
Monteverde Law Firm Investigates Multiple REIT Transactions
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Whitestone REIT and Ares Management, with Whitestone shareholders expected to receive $19.00 per share in cash, significantly enhancing shareholder returns on their investments.
- Assertio Transaction Details: In the deal between Assertio Holdings and Garda Therapeutics, shareholders are expected to receive $18.00 in cash per share plus a contingent value right based on specific milestones, a structure that may attract more investor interest in the company's future growth potential.
- Enhabit Shareholder Vote: Enhabit Inc.'s transaction with Kinderhook Industries is expected to provide shareholders with $13.80 per share in cash, with the shareholder vote scheduled for May 12, 2026, a critical date that will influence the final outcome of the transaction.
- Select Medical Transaction Overview: Shareholders of Select Medical Holdings Corporation are expected to receive $16.50 per share in cash, with the transaction led by Select Medical executives and directors, a structure that may enhance governance transparency and increase shareholder trust.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Enhabit, Inc. (NYSE: EHAB) regarding its sale to Kinderhook Industries, LLC for $13.80 per share in cash, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- Shareholder Rights Protection: The law firm encourages Enhabit shareholders to reach out to discuss their rights and options, emphasizing the provision of legal consultations at no cost, ensuring shareholders are not overlooked in the transaction.
- Other Company Investigations: The inquiry also covers Whitestone REIT (NYSE: WSR) with Ares Management Corporation at $19.00 per unit, and Select Medical Holdings Corporation (NYSE: SEM) with its management for $16.50 per share, highlighting a focus on shareholder interests.
- Legal Remedies: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief measures to protect investors' rights, reflecting a commitment to securities law and fiduciary responsibilities.
See More
Halper Sadeh Investigates Assertio Sale to Garda Therapeutics
- Transaction Investigation: Halper Sadeh LLC is investigating the sale of Assertio Holdings, Inc. to Garda Therapeutics for $18.00 per share in cash and a contingent value right, focusing on whether the best possible price was obtained for shareholders.
- Shareholder Rights: The law firm encourages Assertio shareholders to reach out to learn about their rights and options, emphasizing free consultations to ensure shareholders are not overlooked in the transaction process.
- Compliance Issues: The investigation also examines whether Assertio's board violated federal securities laws and fiduciary duties by failing to conduct a fair sales process and disclose all material information, potentially impacting shareholder decisions.
- Potential Remedies: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders to ensure their legal rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Avanos Medical, Inc.'s sale to American Industrial Partners for $25.00 per share in cash, which may infringe on shareholder rights.
- Transaction Structure Analysis: Leggett & Platt, Incorporated is selling to Somnigroup International Inc. for 0.1455 shares of common stock per share, resulting in Leggett & Platt shareholders owning approximately 9% of the combined company, potentially affecting their future equity.
- Cash Transaction Impact: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash and a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, aiming to provide relief for investors affected by securities fraud and corporate misconduct, emphasizing their expertise in safeguarding investor rights.
See More
ASSERTIO HOLDINGS INC: MAXIM GROUP LOWERS RATING TO HOLD FROM BUY
- Company Update: Assert Holdings has made a strategic decision to cut its rating on MaxIM Group from "buy" to a lower classification.
- Market Impact: This downgrade may influence investor sentiment and trading activity related to MaxIM Group's stock.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Whitestone REIT (NYSE: WSR) for its sale to Ares Management Corporation at $19.00 per share, potentially violating fiduciary duties to shareholders.
- Merger Implications: The merger between McCormick & Company (NYSE: MKC) and Unilever's Foods business will result in McCormick shareholders owning 35.0% of the combined entity, which may affect shareholder rights.
- Acquisition Scrutiny: Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) is under investigation regarding its merger with American Ocean Minerals Corporation, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations aimed at advocating for investors affected by securities fraud and corporate misconduct, highlighting its successful track record in recovering losses for defrauded investors.
See More
Monteverde Law Firm Investigates Multiple REIT Transactions
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Whitestone REIT and Ares Management, with Whitestone shareholders expected to receive $19.00 per share in cash, significantly enhancing shareholder returns on their investments.
- Assertio Transaction Details: In the deal between Assertio Holdings and Garda Therapeutics, shareholders are expected to receive $18.00 in cash per share plus a contingent value right based on specific milestones, a structure that may attract more investor interest in the company's future growth potential.
- Enhabit Shareholder Vote: Enhabit Inc.'s transaction with Kinderhook Industries is expected to provide shareholders with $13.80 per share in cash, with the shareholder vote scheduled for May 12, 2026, a critical date that will influence the final outcome of the transaction.
- Select Medical Transaction Overview: Shareholders of Select Medical Holdings Corporation are expected to receive $16.50 per share in cash, with the transaction led by Select Medical executives and directors, a structure that may enhance governance transparency and increase shareholder trust.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Enhabit, Inc. (NYSE: EHAB) regarding its sale to Kinderhook Industries, LLC for $13.80 per share in cash, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- Shareholder Rights Protection: The law firm encourages Enhabit shareholders to reach out to discuss their rights and options, emphasizing the provision of legal consultations at no cost, ensuring shareholders are not overlooked in the transaction.
- Other Company Investigations: The inquiry also covers Whitestone REIT (NYSE: WSR) with Ares Management Corporation at $19.00 per unit, and Select Medical Holdings Corporation (NYSE: SEM) with its management for $16.50 per share, highlighting a focus on shareholder interests.
- Legal Remedies: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief measures to protect investors' rights, reflecting a commitment to securities law and fiduciary responsibilities.
See More
Halper Sadeh Investigates Assertio Sale to Garda Therapeutics
- Transaction Investigation: Halper Sadeh LLC is investigating the sale of Assertio Holdings, Inc. to Garda Therapeutics for $18.00 per share in cash and a contingent value right, focusing on whether the best possible price was obtained for shareholders.
- Shareholder Rights: The law firm encourages Assertio shareholders to reach out to learn about their rights and options, emphasizing free consultations to ensure shareholders are not overlooked in the transaction process.
- Compliance Issues: The investigation also examines whether Assertio's board violated federal securities laws and fiduciary duties by failing to conduct a fair sales process and disclose all material information, potentially impacting shareholder decisions.
- Potential Remedies: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders to ensure their legal rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Avanos Medical, Inc.'s sale to American Industrial Partners for $25.00 per share in cash, which may infringe on shareholder rights.
- Transaction Structure Analysis: Leggett & Platt, Incorporated is selling to Somnigroup International Inc. for 0.1455 shares of common stock per share, resulting in Leggett & Platt shareholders owning approximately 9% of the combined company, potentially affecting their future equity.
- Cash Transaction Impact: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash and a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, aiming to provide relief for investors affected by securities fraud and corporate misconduct, emphasizing their expertise in safeguarding investor rights.
See More
ASSERTIO HOLDINGS INC: MAXIM GROUP LOWERS RATING TO HOLD FROM BUY
- Company Update: Assert Holdings has made a strategic decision to cut its rating on MaxIM Group from "buy" to a lower classification.
- Market Impact: This downgrade may influence investor sentiment and trading activity related to MaxIM Group's stock.
See More
